| Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma MA Dimopoulos, D Dytfeld, S Grosicki, P Moreau, N Takezako, M Hori, ... New England Journal of Medicine 379 (19), 1811-1822, 2018 | 534 | 2018 |
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma AJ Jakubowiak, D Dytfeld, KA Griffith, D Lebovic, DH Vesole, S Jagannath, ... Blood, The Journal of the American Society of Hematology 120 (9), 1801-1809, 2012 | 516 | 2012 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 378 | 2019 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 318 | 2017 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 248 | 2021 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 192 | 2021 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England journal of medicine 389 (4), 335-347, 2023 | 126 | 2023 |
| LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma MV Mateos, K Weisel, V De Stefano, H Goldschmidt, M Delforge, M Mohty, ... Leukemia 36 (5), 1371-1376, 2022 | 114 | 2022 |
| Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells RM Thompson, D Dytfeld, L Reyes, RM Robinson, B Smith, Y Manevich, ... Oncotarget 8 (22), 35863, 2017 | 110 | 2017 |
| Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy D Dytfeld, M Luczak, T Wrobel, L Usnarska-Zubkiewicz, ... Oncotarget 7 (35), 56726, 2016 | 65 | 2016 |
| Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma JK Jasielec, T Kubicki, N Raje, R Vij, D Reece, J Berdeja, BA Derman, ... Blood, The Journal of the American Society of Hematology 136 (22), 2513-2523, 2020 | 62 | 2020 |
| Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017 A Dmoszyńska, L Usnarska-Zubkiewicz, J Walewski, E Lech-Marańda, ... Acta Haematologica Polonica 48 (2), 55-103, 2017 | 58 | 2017 |
| Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma D Dytfeld, J Jasielec, KA Griffith, D Lebovic, DH Vesole, S Jagannath, ... Haematologica 99 (9), e162, 2014 | 57 | 2014 |
| Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT … T Zimmerman, NS Raje, R Vij, D Reece, JG Berdeja, LA Stephens, ... Blood 128 (22), 675, 2016 | 55 | 2016 |
| Synergistic myeloma cell death via novel intracellular activation of caspase-10–dependent apoptosis by carfilzomib and selinexor S Rosebeck, MM Alonge, M Kandarpa, A Mayampurath, SL Volchenboum, ... Molecular cancer therapeutics 15 (1), 60-71, 2016 | 49 | 2016 |
| Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial MA Dimopoulos, D Dytfeld, S Grosicki, P Moreau, N Takezako, M Hori, ... Journal of Clinical Oncology 41 (3), 568-578, 2023 | 46 | 2023 |
| Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia L Gil, J Styczynski, D Dytfeld, R Debski, M Kazmierczak, B Kolodziej, ... Anticancer research 27 (6B), 4021-4025, 2007 | 33 | 2007 |
| Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma D Dytfeld, M Matuszak, K Lewandowski, M Komarnicki Annals of hematology 87, 253-254, 2008 | 27 | 2008 |
| Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019 K Giannopoulos, K Jamroziak, L Usnarska-Zubkiewicz, D Dytfeld, ... Acta Haematologica Polonica 49 (4), 157-206, 2018 | 25 | 2018 |
Kent A GriffithCenter for Cancer Biostatistics, University of Michigan School of Public HealthVerified email at med.umich.edu
